The following year, Tulinius et al. [46] examined the effect of a single Icelandic founder BRCA2 PV (999del5) on cancer risk among families of 995 breast cancer patients in Iceland, 90 of whom tested positive for the BRCA2 founder. This evidence concerns the gene BRCA2 and breast carcinoma.